Beximco looks beyond Bangladesh with $6.6 sofosbuvir

Bangladesh's Beximco Pharmaceuticals may not be the first onto the local market with its cut-price version of Gilead's hepatitis C blockbuster Sovaldi (sofosbuvir), but the company appears to be pulling out all the stops to establish a stronghold in the market.